Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146562 · ClinicalTrials.gov registry record · Phase 2
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
A Phase 2 study, sponsored by Harold J. Burstein, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT00146562: Completed Phase 2 study, sponsored by Harold J. Burstein, MD, PhD.
NCT00146562 is a Phase 2 study that has completed, run by Harold J. Burstein, MD, PhD. The registered enrollment target is 135 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00146562, a Phase 2 study, has completed, sponsored by Harold J. Burstein, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell growth factor, darbepoetin alfa(Aranesp) can reduce the need for blood transfusion in chemotherapy recipients.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Darbepoetin Alfa
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2003-07 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00146562
The ClinicalTrials.gov registry entry for NCT00146562 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harold J. Burstein, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00146562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00146562 about?
NCT00146562 is a clinical study titled "Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer". The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell growth factor, darbepoetin alfa(Aranesp) can reduce the need for blood transfusion in chemotherapy recipients.
What is the current status of trial NCT00146562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2003-07. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00146562?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), Darbepoetin Alfa (DRUG), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT00146562?
This trial is sponsored by Harold J. Burstein, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.